Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on June 6, 2024, for the resale of Ordinary Shares represented by Depositary Shares. This includes Ordinary Shares issuable upon the exercise of Series G, Series H, and Warrant Agent Warrants. The selling shareholders, including investment funds and broker-dealers, may sell these securities on the open market or through private transactions. The registration allows for the sale of these securities without Biodexa Pharmaceuticals being required to maintain the registration statement's effectiveness, provided the securities can be sold without registration due to Rule 144 or other exemptions. The company has agreed to indemnify the selling shareholders against certain liabilities, including those under the Securities Act of 1933. Biodexa Pharmaceuticals will not receive any proceeds from the sale of the securities by the selling shareholders.

Biodexa Pharmaceuticals PLC, a clinical-stage biopharmaceutical company, has filed a registration statement with the U.S. Securities and Exchange Commission (SEC) on June 6, 2024, for the resale of Ordinary Shares represented by Depositary Shares. This includes Ordinary Shares issuable upon the exercise of Series G, Series H, and Warrant Agent Warrants. The selling shareholders, including investment funds and broker-dealers, may sell these securities on the open market or through private transactions. The registration allows for the sale of these securities without Biodexa Pharmaceuticals being required to maintain the registration statement's effectiveness, provided the securities can be sold without registration due to Rule 144 or other exemptions. The company has agreed to indemnify the selling shareholders against certain liabilities, including those under the Securities Act of 1933. Biodexa Pharmaceuticals will not receive any proceeds from the sale of the securities by the selling shareholders.